Overview#
Jones Trading has raised its price target for Sionna Therapeutics (NASDAQ:SION) from $52 to $63 while keeping a Buy rating on the stock. Currently, shares are trading at $39.21, indicating significant potential for growth based on the new target. Despite a recent 6% decline, the stock has impressively returned 226% over the past year.
Trial Progress#
The increase in the price target follows the completion of enrollment in Sionna's Phase 2a PreciSION CF trial. This trial is testing SION-719, a novel treatment designed to stabilize a specific part of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, in combination with the standard treatment, Trikafta, for patients with a specific genetic mutation in cystic fibrosis. Results from this trial are expected to be released this summer.
Analyst Insights#
Jones Trading has raised the probability of success for Sionna’s treatment from 25% to 35%, which contributed to the new price target. Analysts maintain a Strong Buy consensus on the stock, although some assessments suggest that the shares may currently be priced above their fair value.
Additional Developments#
In addition to Jones Trading's update, Guggenheim has also increased its price target for Sionna Therapeutics to $50 while maintaining a Buy rating. Furthermore, Citizens has begun coverage of Sionna with a Market Outperform rating and a price target of $63. These developments indicate a growing confidence among analysts regarding Sionna's potential in the market, especially as the company reported $310.3 million in cash at the end of fiscal year 2025, which is expected to last until 2028.